Precision BioSciences
DTILNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $9.50 Prior regular-session close from the quote source.
- $8.93–$9.59 Regular-session low and high so far today.
- 251.7K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Jan 12 projected Projected for 2027-01-12 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $3.53–$11.29 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own DTIL if Precision converts its science into partner validation or clinical milestones before cash burn forces dilution.
DTIL price history
Loading recent earnings…
Investment thesis
What must happen next
Partners must keep choosing Precision’s platform because specialized gene-editing capabilities are more valuable to access externally than to replicate internally; if partner demand fades, the model loses its main non-dilutive funding source.HoldingMateriality: High
GAAP annual revenue from customer contracts was $25.098 million for the year ended December 31, 2022, $48.727 million for 2023, and $68.696 million for 2024, showing that external parties have paid for Precision’s work. If this holds, collaboration and milestone revenue can extend runway and validate the platform; if it breaks, shareholders fund the science mostly through dilution.
Watch: Large pharma partners internalize comparable gene-editing capabilities instead of licensing Precision’s platform.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue from customer contracts was $25.098 million for the year ended December 31, 2022, $48.727 million for 2023.
Open source ↗Precision’s equity value depends on having enough cash runway to reach validation events before capital markets or partners force unfavorable financing terms.HoldingMateriality: High
Cash and cash equivalents were $86.076 million at June 30, 2026. Adequate runway lets shareholders retain upside from clinical or partnering catalysts; inadequate runway transfers value to new capital providers.
Watch: Clinical development spending accelerates materially as programs advance without matching partner funding.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash and cash equivalents were $86.076 million at June 30, 2026.
Open source ↗The collaboration model creates value only if milestones and license economics periodically absorb Precision’s research cost base; otherwise the company remains a cash-burning R&D organization with little operating leverage.HoldingMateriality: Medium
GAAP annual operating loss narrowed to $26.162 million for the year ended December 31, 2024 when annual revenue was elevated. Operating leverage from partner economics would make each validation event more valuable to owners; failure means even scientific progress may require repeated external capital.
Watch: Partner programs fail to advance to milestone-triggering events.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating loss narrowed to $26.162 million for the year ended December 31, 2024 when annual revenue was elevated.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Partners must keep choosing Precision’s platform because specialized gene-editing capabilities are more valuable to access externally than to replicate internally; if partner demand fades, the model loses its main non-dilutive funding source. If this holds, collaboration and milestone revenue can extend runway and validate the platform; if it breaks, shareholders fund the science mostly through dilution.
Precision’s equity value depends on having enough cash runway to reach validation events before capital markets or partners force unfavorable financing terms. Adequate runway lets shareholders retain upside from clinical or partnering catalysts; inadequate runway transfers value to new capital providers.
The collaboration model creates value only if milestones and license economics periodically absorb Precision’s research cost base; otherwise the company remains a cash-burning R&D organization with little operating leverage. Operating leverage from partner economics would make each validation event more valuable to owners; failure means even scientific progress may require repeated external capital.
All standing thesis claims
Original report summary
Precision converts its science into partner validation or clinical milestones before cash burn forces dilution.
Bull case and bear case
Bull case and bear case for Precision Biosciences
Where the evidence on Precision Biosciences stands: Holding on the latest evidence (Nov 4, 2026). Of its 3 thesis points, 3 holding.
Bull case: what the evidence supports
Partners must keep choosing Precision’s platform because specialized gene-editing capabilities are more valuable to access externally than to replicate internally; if partner demand fades, the model loses its main non-dilutive funding source.
Precision’s equity value depends on having enough cash runway to reach validation events before capital markets or partners force unfavorable financing terms.
The collaboration model creates value only if milestones and license economics periodically absorb Precision’s research cost base; otherwise the company remains a cash-burning R&D organization with little operating leverage.
Bear case: what would count against it
Large pharma partners internalize comparable gene-editing capabilities instead of licensing Precision’s platform.
Clinical development spending accelerates materially as programs advance without matching partner funding.
Partner programs fail to advance to milestone-triggering events.
Thesis-Break Engine
What has broken in Precision Biosciences’s thesis
Each break OptimistFi flagged on Precision Biosciences, dated — with what has historically followed the same kind of break across the market, not a forecast for Precision Biosciences.
- Revenue decline
Across all companies, this kind of break has happened 8,727 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 37% of them trailed it by 10 points or more.
Early warning
The break condition read on the trailing twelve months through Precision Biosciences’s latest quarterly report, ahead of the annual figure it is written on.
- Revenue decline, trailing 12 months
Across all companies, this kind of early warning has happened 3,039 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 32% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Precision Biosciences filed an SEC 8-K on 2026-11-03: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedRegulation FD disclosure.
Precision Biosciences filed an SEC 8-K on 2026-08-24: Regulation FD disclosure. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Precision Biosciences filed an SEC 8-K on 2026-08-06: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Large pharma partners internalize comparable gene-editing capabilities instead of licensing Precision’s platform.
- Clinical development spending accelerates materially as programs advance without matching partner funding.
- Partner programs fail to advance to milestone-triggering events.
DTIL news
Loading headlines…
Financial statements
DTIL income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
DTIL: quick answers
- When does Precision Biosciences (DTIL) report earnings next?
- Precision Biosciences's next results are projected for January 12, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 3, 2026. Earnings calendar
- What is DTIL's short interest?
- As of October 30, 2026, 2.1M DTIL shares were sold short, 7.51% of its shares outstanding, down 11.0% from the count before. At the stock's average daily volume that is 11 days to cover. FINRA publishes the count twice a month. DTIL short interest history